Last reviewed · How we verify
Topical Diclofenac gel 1% — Competitive Intelligence Brief
marketed
Nonsteroidal anti-inflammatory drug (NSAID)
COX-1 and COX-2
Rheumatology / Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Topical Diclofenac gel 1% (Topical Diclofenac gel 1%) — University of California, Davis. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Topical Diclofenac gel 1% TARGET | Topical Diclofenac gel 1% | University of California, Davis | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | COX-1 and COX-2 | |
| Cytotec | Misoprostol | Pfizer | marketed | NSAID combined with prostaglandin analog | Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors | 1988-01-01 |
| Bromfenac Ophthalmic Solution B | Bromfenac Ophthalmic Solution B | Bausch & Lomb Incorporated | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | |
| Tinoridine HCl | Tinoridine HCl | Takeda | marketed | Non-steroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | |
| Prolensa 0.07% Ophthalmic Solution | Prolensa 0.07% Ophthalmic Solution | Nicole Fram M.D. | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase (COX-1 and COX-2) | |
| aspirin and [NSAID] | aspirin and [NSAID] | POZEN | marketed | NSAID combination | Cyclooxygenase (COX-1 and COX-2) | |
| Voltaren® Gel | Voltaren® Gel | Glenmark Pharmaceuticals Ltd. India | marketed | Topical NSAID | COX-1 and COX-2 enzymes |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)
- Università degli Studi di Brescia · 4 drugs in this class
- Bausch & Lomb Incorporated · 4 drugs in this class
- Bayer · 3 drugs in this class
- Pfizer · 3 drugs in this class
- Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
- Organon and Co · 3 drugs in this class
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
- Bezmialem Vakif University · 2 drugs in this class
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
- Center For Excellence In Eye Care · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Topical Diclofenac gel 1% CI watch — RSS
- Topical Diclofenac gel 1% CI watch — Atom
- Topical Diclofenac gel 1% CI watch — JSON
- Topical Diclofenac gel 1% alone — RSS
- Whole Nonsteroidal anti-inflammatory drug (NSAID) class — RSS
Cite this brief
Drug Landscape (2026). Topical Diclofenac gel 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-diclofenac-gel-1. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab